Parmax Pharma reports acquisition of 2.49 lakh shares, total insider stake now 27.2%

What Parmax Pharma announced

Parmax Pharma Ltd filed a disclosure with BSE on 19 June 2026 under Regulation 18(6) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing informs that Abhay Chinubhai Shah (identified as PAC 8) acquired 2,49,394 equity shares of the company on 18 June 2026 through an off‑market transaction. The acquisition is part of a broader share‑holding pattern involving several members of the Shah family and related persons, collectively referred to as PACs (Persons Acting in Concert).

"Abhay Chinubhai Shah has been disclosed as PAC 8 in the public announcement dated June 08, 2026 and the detailed public statement published on June 15, 2026."

The filing was submitted by Sunil Chinubhai Shah and Dhiren Chandulal Shah, who are listed as Acquirer 1 and Acquirer 2 respectively, on behalf of the group of PACs.

Details of the share acquisition

• Acquirer: Abhay Chinubhai Shah (PAC 8) – a member of the Shah family and a Person Acting in Concert.
• Number of shares acquired: 2,49,394 equity shares, each with a face value of Rs 10.
• Date of acquisition: 18 June 2026.
• Mode of acquisition: Off‑market transaction (i.e., a private deal outside the stock exchange).
• Purchase price: Rs 35 per share. This translates to a total consideration of roughly Rs 8.73 crore (2,49,394 × Rs 35).
• Source of shares: The shares were transferred from Pradeep Gosalia (as per the tabular disclosure).
• Demat status: The shares have not yet been credited to the demat account of PAC 8 at the time of filing.

The filing also lists a total of ten PACs, including Dhairya Dhiren Shah, Hiren Pravin Doshi, Sheetal Hiren Doshi, Nirmal Sunilbhai Shah, Rupa Sunil Shah, Vijaykumar Natvarlal Shiyani, Kamlesh Natvarlal Shiyani, Umang Alkesh Gosalia, and Meena Alkesh Gosalia. The disclosure confirms that the acquisition by PAC 8 was already disclosed in earlier public announcements dated 8 June 2026 and 15 June 2026.

Shareholding impact

Before the 18 June transaction, the combined shareholding of the Shah family and the listed PACs stood at 7,68,320 shares, representing 20.54% of Parmax Pharma’s total equity. After the addition of the 2,49,394 shares, the total holding rose to 10,17,714 shares, or 27.20% of the company’s equity.

This increase in stake consolidates the family’s voting power and may influence future corporate decisions that require shareholder approval. However, the filing does not indicate any immediate change in board composition or management.

Key facts at a glance

Why this matters for investors

The disclosure is a statutory requirement under SEBI’s SAST regulations, which aim to provide transparency when a party acquires a material stake in a listed company. For existing shareholders, the key implications are:

1. Voting power concentration – The Shah family and related PACs now control over a quarter of the voting capital, which could affect resolutions that need a simple majority or higher thresholds.
2. Potential for future transactions – The increase may be a precursor to further share purchases, a possible open‑offer trigger, or a strategic move to consolidate control.
3. No immediate dilution – The transaction was an off‑market purchase from an existing shareholder, so there is no fresh issuance of shares that would dilute existing shareholders.
4. Regulatory compliance – The filing demonstrates compliance with SEBI rules, reducing regulatory risk for the company.
5. Liquidity considerations – Since the shares are not yet in the demat account of PAC 8, the actual transfer of voting rights may be pending, but the intent is clearly documented.

Investors should monitor any subsequent filings that may disclose further share movements, changes in the composition of the PACs, or any board‑level decisions that could be influenced by the heightened family stake.

Conclusion

Parmax Pharma’s 19 June 2026 filing confirms that PAC 8, Abhay Chinubhai Shah, acquired 2,49,394 shares at Rs 35 each, raising the collective holding of the Shah family and related persons to 27.20% of the company. The shares are yet to be credited to the acquirer’s demat account, and the filing satisfies SEBI’s disclosure requirements. Future disclosures will reveal whether additional share acquisitions are planned or if the increased stake translates into governance changes.